Motus GI Completes First Clinical Evaluation of New Pure-Vu® Gastro in Upper Gastrointestinal (GI) Procedures to Support FDA Submission
May 17, 2023 08:30 ET
|
Motus GI Holdings, Inc.
- Pure-Vu Gastro achieves high usability scores in supporting upper endoscopy procedures with first time users - - On track to submit a 510(k) to the U.S. FDA for the Pure-Vu Gen 4 Gastro device in...
Motus GI Announces DDW 2023 Clinical Study Presentation Showing Pure-Vu EVS Drove a 33% Hospital-Wide Improvement in Incomplete Bowel Prep Rate at Minneapolis VA Medical Center
May 11, 2023 07:00 ET
|
Motus GI Holdings, Inc.
FORT LAUDERDALE, Fla., May 11, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve...
Motus GI Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023 16:05 ET
|
Motus GI Holdings, Inc.
■Oral presentation at the Digestive Disease Week 2023 featured positive clinical data showing a reduction of 33% in incomplete bowel prep (IBP)in just six months after implementation of the Pure-Vu®...
Motus GI Announces Executive Leadership Restructuring and Additional Cost Saving Initiatives to Support Near-Term Milestones
April 13, 2023 16:05 ET
|
Motus GI Holdings, Inc.
Tim Moran transitions from Chief Executive Officer to Chairman of the Board and Mark Pomeranz appointed Chief Executive Officer to lead next phase of Company Restructuring plan reduces operating...
Motus GI Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 31, 2023 16:05 ET
|
Motus GI Holdings, Inc.
The Company continues its exploration process to target strategic and financing alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder valueThe Company...
Motus GI Announces Exploration of Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring Plan
January 10, 2023 08:30 ET
|
Motus GI Holdings, Inc.
Lake Street Capital Markets LLC engaged to act as an advisor to the CompanyBoard of Directors approved restructuring program with the objective of preserving capital to align with strategic process...
Motus GI Announces Improvement of Pure-Vu® EVS System for Use in Upper Gastrointestinal (GI) Bleeding Procedures Following Successful Pre-Clinical Tests
December 21, 2022 08:00 ET
|
Motus GI Holdings, Inc.
Pre-clinical tests show enhanced functionality of Pure-Vu EVS that can enable physicians to overcome common visualization challenges encountered during emergency upper GI bleeding proceduresAdditional...
Motus GI Reports Third Quarter 2022 Financial Results and Provides Business Update
November 14, 2022 16:05 ET
|
Motus GI Holdings, Inc.
Pure-Vu EVS approved for use at 25 hospitals since launch in March 2022, resulting in highest quarterly revenue reported in the Company’s historyRecently named a Sole Source Supplier by the Department...
Motus GI to Release Third Quarter Results and Provide a Business Update on November 14
October 31, 2022 16:05 ET
|
Motus GI Holdings, Inc.
FORT LAUDERDALE, Fla., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that...
Motus GI Announces Positive Clinical Data for Pure-Vu EVS in Three Poster Presentations at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
October 24, 2022 08:30 ET
|
Motus GI Holdings, Inc.
Positive clinical data from feasibility and efficacy study of the Pure-Vu EVS conducted by Minneapolis VA Health Care System Overview of the results from an inpatient colonoscopy conducted at an ICU...